Marcel A Mller

List of Publications by Year in Descending Order

74 papers	25,745 citations	49 h-index	77 g-index
77 ext. papers	32,688 ext. citations	14.1 avg, IF	7.51 L-index

#	Paper	IF	Citations
74	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4 T Cells following BNT162b2 Vaccination in the Elderly.. *Journal of Immunology*, **2022**,	5.3	4
73	Antiviral and Immunomodulatory Effects of Root Extract EPs 7630 in SARS-CoV-2-Infected Human Lung Cells. *Frontiers in Pharmacology*, **2021**, 12, 757666	5.6	3
72	Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. *Lancet Microbe, The*, **2021**, 2, e311-e319	22.2	119
71	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. *Nature Communications*, **2021**, 12, 2117	17.4	34
70	Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. *Lancet Microbe, The*, **2021**, 2, e210-e218	22.2	18
69	Impaired performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests at elevated and low temperatures. *Journal of Clinical Virology*, **2021**, 138, 104796	14.5	15
68	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. *Clinical Microbiology and Infection*, **2021**, 27, 1520.e7-1520.e10	9.5	2
67	SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. *Nature Communications*, **2021**, 12, 3818	17.4	53
66	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. *Frontiers in Immunology*, **2021**, 12, 629185	8.4	11
65	Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. *Science*, **2021**, 374, eabh1823	33.3	53
64	Functional comparison of MERS-coronavirus lineages reveals increased replicative fitness of the recombinant lineage 5. *Nature Communications*, **2021**, 12, 5324	17.4	0
63	Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. *Nature*, **2020**, 582, 561-565	50.4	205
62	Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. *Emerging Infectious Diseases*, **2020**, 26, 1478-1488	10.2	1055
61	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, **2020**, 181, 271-280.e8	56.2	10629
60	Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. *Emerging Microbes and Infections*, **2020**, 9, 155-168	18.9	53
59	Virological assessment of hospitalized patients with COVID-2019. *Nature*, **2020**, 581, 465-469	50.4	4168
58	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature*, **2020**, 587, 270-274	50.4	688

57	Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	281
56	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. *Frontiers in Immunology*, **2020**, 11, 628971	8.4	21
55	Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus. *Emerging Infectious Diseases*, **2019**, 25, 1878-1883	10.2	12
54	Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar. *Journal of Immunology Research*, **2019**, 2019, 1386740	4.5	32
53	SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. *Nature Communications*, **2019**, 10, 5770	17.4	192
52	Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. *Journal of Virology*, **2019**, 93,	6.6	84
51	The papain-like protease determines a virulence trait that varies among members of the SARS-coronavirus species. *PLoS Pathogens*, **2018**, 14, e1007296	7.6	49
50	Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. *Antiviral Therapy*, **2018**, 23, 617-622	1.6	216
49	Factors determining human-to-human transmissibility of zoonotic pathogens via contact. *Current Opinion in Virology*, **2017**, 22, 7-12	7.5	10
48	Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. *Diagnostic Microbiology and Infectious Disease*, **2017**, 89, 106-111	2.9	62
47	Serologic Evaluation of MERS Screening Strategy for Healthcare Personnel During a Hospital-Associated Outbreak. *Infection Control and Hospital Epidemiology*, **2017**, 38, 234-238	2	12
46	No Serologic Evidence of Middle East Respiratory Syndrome Coronavirus Infection Among Camel Farmers Exposed to Highly Seropositive Camel Herds: A Household Linked Study, Kenya, 2013. *American Journal of Tropical Medicine and Hygiene*, **2017**, 96, 1318-1324	3.2	28
45	Time Course of MERS-CoV Infection and Immunity in Dromedary Camels. *Emerging Infectious Diseases*, **2016**, 22, 2171-2173	10.2	31
44	Link of a ubiquitous human coronavirus to dromedary camels. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 9864-9	11.5	84
43	Epithelial cell lines of the cotton rat (Sigmodon hispidus) are highly susceptible in vitro models to zoonotic Bunya-, Rhabdo-, and Flaviviruses. *Virology Journal*, **2016**, 13, 74	6.1	6
42	Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. *Clinical Infectious Diseases*, **2016**, 62, 477-483	11.6	259
41	MERS-CoV Antibodies in Humans, Africa, 2013-2014. *Emerging Infectious Diseases*, **2016**, 22, 1086-9	10.2	43
40	p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E5192-201	11.5	104

39	Infectious Middle East Respiratory Syndrome Coronavirus Excretion and Serotype Variability Based on Live Virus Isolates from Patients in Saudi Arabia. *Journal of Clinical Microbiology*, **2015**, 53, 2951-5	9.7	43
38	Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. *Lancet Infectious Diseases, The*, **2015**, 15, 559-64	25.5	227
37	Serologic assessment of possibility for MERS-CoV infection in equids. *Emerging Infectious Diseases*, **2015**, 21, 181-2	10.2	40
36	Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity. *Journal of Infectious Diseases*, **2015**, 211, 889-97	7	33
35	Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013-2014. *Emerging Infectious Diseases*, **2015**, 21, 1422-5	10.2	63
34	Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. *ELife*, **2015**, 4,	8.9	76
33	Transmission of MERS-coronavirus in household contacts. *New England Journal of Medicine*, **2014**, 371, 828-35	59.2	288
32	Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections--needs, advances, and future prospects. *Lancet Infectious Diseases, The*, **2014**, 14, 1123-1135	25.5	105
31	Serological assays for emerging coronaviruses: challenges and pitfalls. *Virus Research*, **2014**, 194, 175-83	6.4	270
30	Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. *Journal of Infectious Diseases*, **2014**, 209, 243-6	7	72
29	Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. *PLoS Pathogens*, **2014**, 10, e1004166	7.6	113
28	Replicative Capacity of MERS Coronavirus in Livestock Cell Lines. *Emerging Infectious Diseases*, **2014**, 20, 276-9	10.2	75
27	Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. *Emerging Infectious Diseases*, **2014**, 20, 552-9	10.2	187
26	Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. *Emerging Infectious Diseases*, **2014**, 20, 1012-5	10.2	260
25	Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. *Emerging Infectious Diseases*, **2014**, 20, 1319-22	10.2	156
24	MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. *Emerging Infectious Diseases*, **2014**, 20, 2093-5	10.2	206
23	Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. *Lancet Infectious Diseases, The*, **2013**, 13, 859-66	25.5	523
22	In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection. *Virology Journal*, **2013**, 10, 359	6.1	96

21	Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature*, **2013**, 495, 251-4	50.4	1362
20	Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. *Lancet Infectious Diseases, The*, **2013**, 13, 745-51	25.5	288
19	Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. *MBio*, **2013**, 4, e00611-12	7.8	151
18	Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. *Journal of Virology*, **2013**, 87, 12489-95	6.6	143
17	Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. *Virus Research*, **2012**, 165, 112-7	6.4	155
16	Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. *MBio*, **2012**, 3,	7.8	154
15	Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. *Journal of Virology*, **2011**, 85, 13363-72	6.6	219
14	Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *Journal of Virology*, **2011**, 85, 4122-34	6.6	711
13	Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. *Journal of Infectious Diseases*, **2011**, 204 Suppl 3, S840-9	7	54
12	The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. *PLoS Pathogens*, **2011**, 7, e1002331	7.6	292
11	Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. *Emerging Infectious Diseases*, **2009**, 15, 1377-84	10.2	170
10	Plaque assay for human coronavirus NL63 using human colon carcinoma cells. *Virology Journal*, **2008**, 5, 138	6.1	51
9	Coronavirus antibodies in African bat species. *Emerging Infectious Diseases*, **2007**, 13, 1367-70	10.2	55
8	Serum but not mucosal antibody responses are predicted by pre-existing SARS-CoV-2 spike cross-reactive CD4+ T cells following BNT162b2 vaccination in the elderly		1
7	Virological assessment of hospitalized cases of coronavirus disease 2019		158
6	SARS-CoV-2 specific antibody responses in COVID-19 patients		88
5	Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics		53
4	Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors		88

3	Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests	38
2	Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination	3
1	Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated temperatures	3